Detalhe da pesquisa
1.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Nat Commun
; 15(1): 1700, 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402224
2.
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Blood Adv
; 6(2): 473-485, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34495306